Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 6
Submit an article Journal homepage
480
Views
6
CrossRef citations to date
0
Altmetric
Drug Profile

The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis

Nicole C. RouseDepartment of Osteopathic and Neuromuscular Medicine, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA
,
Michael E. FarhangianCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA
,
Brooke WehausenCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA
&
Steven R. FeldmanCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA;Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA;Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USACorrespondence[email protected]
Pages 877-884 | Published online: 21 Oct 2015

References

* This paper discusses the impact of psoriasis.

  • Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–967.e5. DOI:10.1016/j.jaad.2015.02.1099.
  • Foundation/USA NP. National Psoriasis Foundation Data 2004 [cited 2015 Apr 5]. Available from: http://www.psoriasis.org.
  • Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151:651. DOI:10.1001/jamadermatol.2014.3593.
  • Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46–54. DOI:10.1001/archdermatol.2009.319.
  • Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context. 2014;3:212266. DOI:10.7573/dic.212266.
  • Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490–500. DOI:10.1016/j.jaad.2006.05.048.
  • Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4(2):559–568.
  • Ismaila AS, Sayani AP, Marin M, et al. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med. 2013;13:70. DOI:10.1186/1471-2466-13-70.
  • Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432–1440. DOI:10.1111/j.1365-4632.2011.05359.x.
  • Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20(12):1929–1936. DOI:10.1185/030079904X15192.
  • Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123–127. DOI:10.1159/000090652.
  • Han C, Lofland JH, Zhao N, et al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10(8):843–850.
  • Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. DOI:10.1001/jama.296.14.1735.
  • Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–835. DOI:10.1016/j.jaad.2006.08.040.
  • Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–640. DOI:10.1016/S0140-6736(09)60140-9.
  • Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. DOI:10.1016/S0140-6736(08)60725-4.
  • Kim IH, West CE, Kwatra SG, et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol. 2012;13(6):365–374. DOI:10.2165/11633110-000000000-00000.
  • Nast A, Jacobs A, Rosumeck S, et al. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015. DOI:10.1038/jid.2015.206.
  • Epocrates. Ustekinumab [cited 2015 Mar 5]. Available from: https://online.epocrates.com/noFrame/showPage?method=drugs&MonographId=5577&ActiveSectionId=10.
  • Sandoval LF, Huang KE, Feldman SR. Adherence to ustekinumab in psoriasis patients. J Drugs Dermatol. 2013;12(10):1090–1092.
  • Ross C, Marshman G, Grillo M, et al. Biological therapies for psoriasis: adherence and outcome analysis from a clinical perspective. Aust J Dermatol. 2015. DOI:10.1111/ajd.12294.
  • Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41–55. DOI:10.1016/j.det.2014.09.004.
  • Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571–579. DOI:10.1016/j.jaad.2009.11.012.
  • Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300–312.
  • D’Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589–598. DOI:10.1016/j.jaad.2014.11.028.
  • Secrest AM, Matinrazm A, Ferris LK. Efficacy, safety, and out-of-pocket costs are the most important factors to patients in choosing a psoriasis therapy. J Clin Aesthet Dermatol. 2014;7(12):30–33.
  • Reich K, Puig L, Paul C, et al. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol. 2014;170(2):435–444. DOI:10.1111/bjd.12643.
  • Sorenson E, Koo J. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: providing clarity to an opaque topic. J Dermatol Treat. 2015;1–9. DOI:10.3109/09546634.2015.1027167.
  • Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–1383. DOI:10.1111/bjd.13469.
  • Mansouri Y, Goldenberg G. Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol. 2015;8(2):30–42.
  • Meng Y, Dongmei L, Yanbin P, et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014;39(6):696–707. DOI:10.1111/ced.12390.
  • STELARA. Stelara Prescribing Information: Janssen [cited 2015 Apr 26]. Available from: http://www.stelarainfo.com/pdf/PrescribingInformation.pdf.
  • Liu Y, Gong JP, Li WF. Therapeutic effect and safety of ustekinumab for plaque psoriasis: a meta-analysis. Chin Med Sci J. 2014;29(3):131–138.
  • Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13(12):1441–1448.
  • Tzellos T, Kyrgidis A, Trigoni A, et al. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol. 2012;4(3):320–323. DOI:10.4161/derm.23100.
  • Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment And Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
  • Korn LM, Reichert S, Simon T, et al. Improving physicians’ knowledge of the costs of common medications and willingness to consider costs when prescribing. J Gen Intern Med. 2003;18(1):31–37.
  • Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. DOI:10.1111/bjd.12214.

* This study analyzed indirect costs of psoriasis.

  • Schmitt-Rau K, Rosenbach T, Radtke MA, et al. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatology. 2010;221(3):236–242. DOI:10.1159/000320111.
  • Avgerinou G, Bassukas I, Chaidemenos G, et al. Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece. BMC Dermatol. 2012;12:10. DOI:10.1186/1471-5945-12-10.
  • Igarashi A, Kuwabara H, Fahrbach K, et al. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatol Treat. 2013;24(5):351–355. DOI:10.3109/09546634.2012.697111.

* This study analyzed the cost-efficacy of ustekinumab for a long period of time.

  • Pan F, Brazier NC, Shear NH, et al. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14(5):652–656. DOI:10.1016/j.jval.2011.01.006.

* This paper discussed ustekinumab’s direct and indirect cost-reduction.

  • Chi CC, Wang SH. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. Biomed Res Int. 2014;2014:862851. DOI:10.1155/2014/862851.
  • Ferrandiz C, Garcia A, Blasco AJ, et al. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2012;26(6):768–777. DOI:10.1111/j.1468-3083.2011.04357.x.
  • Galvan-Banqueri M, Marin Gil R, Santos Ramos B, et al. Biological treatments for moderate-to-severe psoriasis: indirect comparison. J Clin Pharm Ther. 2013;38(2):121–130. DOI:10.1111/jcpt.12044.
  • Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. PharmacoEconomics. 2013;31(9):823–839. DOI:10.1007/s40273-013-0078-x.
  • Wang SH, Chi CC, Hu S. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. Int J Dermatol. 2014;53(9):1151–1156. DOI:10.1111/ijd.12462.
  • Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807–816. DOI:10.1111/j.1365-2133.2010.09944.x.
  • Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatol Treat. 2011;22(6):337–347. DOI:10.3109/09546634.2010.499931.
  • Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209.
  • Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatol Treat. 2005;16(1):37–42. DOI:10.1080/09546630510025941.

* This paper is a complete review of the cost of psoriasis treatment.

  • Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19(8):621–630.
  • Feldman SR, Burudpakdee C, Gala S, et al. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):685–705. DOI:10.1586/14737167.2014.933671.
  • Sawyer LM, Wonderling D, Jackson K, et al. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis. Pharmacoeconomics. 2015;33(2):163–177. DOI:10.1007/s40273-014-0226-y.
  • Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–672. DOI:10.1111/bjd.12422.
  • Korn LM, Reichert S, Simon T, et al. Improving physicians’ knowledge of the costs of common medications and willingness to consider costs when prescribing. J Gen Intern Med. 2003;18(1):31–37.
  • Buzney CD, Peterman C, Saraiya A, et al. Clearance of psoriasis: the impact of private versus public insurance. J Drugs Dermatol. 2015;14(2):119–125.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.